Moderna

Can its Vaccine Live Up to the Hype?

Published July 9, 2020

Download the report

“By completing this form you agree to the processing of your personal information submitted through this form in accordance with CFRA’s Privacy Notice located at https://cfraresearch.com/legal/ and the receipt of communications about CFRA and CFRA’s services.”

Key Takeaways

 

  • mRNA-based vaccines, which have never before been approved by the FDA, may have their breakout moment with Covid-19.

  • Clinical studies and scientific research suggest that mRNA therapies could alter the R&D landscape of the biopharmaceutical industry. 

  • Moderna, a leader in mRNA therapeutics, is a frontrunner in the race to develop a Covid-19 vaccine.

  • We view FDA approval of MRNA’s Covid-19 vaccine as likely in 2021 and we anticipate that positive data catalysts will drive share upside in the near term

 

 

 

Please visit our website for more examples of CFRA's fundamental research.